High But Inequitable COVID-19 Vaccine Uptake Among Patients with Inflammatory Bowel Disease

Clin Gastroenterol Hepatol. 2022 Jul;20(7):1606-1608.e2. doi: 10.1016/j.cgh.2021.12.013. Epub 2021 Dec 9.

Abstract

Coronavirus disease 2019 (COVID-19) vaccines are recommended for all patients with inflammatory bowel disease (IBD).1 Patients with IBD historically have had low vaccine uptake relative to the general population.2 However, a recent survey suggested a rate higher than that of the general population with regard to COVID-19 vaccine intent among the IBD population. Their study was limited being that 96% of the patients surveyed identified as White, and 88% had attained a bachelor's degree or higher level of education.3 Therefore, these findings may not be representative of the IBD population as a whole. Previous studies have indeed identified disparities in influenza vaccine uptake within the IBD population.4,5.

Publication types

  • Letter

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • Inflammatory Bowel Diseases*
  • Influenza Vaccines*
  • Surveys and Questionnaires

Substances

  • COVID-19 Vaccines
  • Influenza Vaccines